Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Clinical Trials01:16

Clinical Trials

7.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.1K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

168
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
168
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

326
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
326
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

Trends in Alcohol-Related Deaths in the United States Over 55 Years: 1968-2023.

Alcohol, clinical & experimental research·2026
Same author

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same author

Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy.

Circulation. Heart failure·2026
Same author

Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity.

European heart journal·2026
Same author

Response by Fonarow et al to Letter Regarding Article, "Improving Heart Failure Quality of are Over the First Twenty Years: The Get With The Guidelines-Heart Failure Program".

Circulation. Heart failure·2026

Related Experiment Video

Updated: Sep 3, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.9K

Cardiovascular Safety Reporting in Contemporary Breast Cancer Clinical Trials.

Arsalan Hamid1, Markus S Anker2,3,4, John C Ruckdeschel5

  • 1Department of Medicine University of Mississippi Medical Center Jackson MS.

Journal of the American Heart Association
|July 25, 2022
PubMed
Summary

Breast cancer trials often exclude patients with cardiovascular conditions and lack routine safety monitoring. This may lead to underestimating the cardiovascular risks of cancer therapies in clinical practice.

Keywords:
cancer therapycardiovascular diseasecardio‐oncologypharmacotherapysafety

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K

Related Experiment Videos

Last Updated: Sep 3, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
11:38

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

46.9K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K

Area of Science:

  • Cardiology
  • Oncology
  • Clinical Trials

Background:

  • Cancer therapies can cause cardiovascular harm, sometimes appearing in later-phase trials.
  • Focusing on breast cancer, this study examines cardiovascular safety reporting in phase 2 and 3 trials.
  • Cardiovascular risks of cancer drugs may be underestimated due to trial limitations.

Purpose of the Study:

  • To assess the reporting of cardiovascular safety monitoring and outcomes in contemporary phase 2 and 3 breast cancer clinical trials.
  • To identify patterns in patient exclusion based on cardiovascular conditions and the reporting of adverse cardiovascular events.
  • To evaluate the methods used for cardiovascular safety assessment in these trials.

Main Methods:

  • Searched Embase and Medline for phase 2 and 3 breast cancer pharmacotherapy trials.
  • Analyzed trial exclusion criteria for cardiovascular conditions, adverse event reporting, and safety assessments (imaging, ECG, troponin, natriuretic peptides).
  • Used Fisher's exact test to compare reporting frequencies across trial types.

Main Results:

  • Fifty trials were included; 84% excluded patients with cardiovascular conditions, notably heart failure (62%).
  • Adverse cardiovascular events were reported in 86% of trials, but comprehensive safety assessments were lacking in 46%.
  • Cardiovascular safety assessments were more common in industry-funded trials and those using targeted/immunotherapy agents.

Conclusions:

  • Contemporary later-phase breast cancer trials significantly under-represent patients with pre-existing cardiovascular disease.
  • Routine cardiovascular safety monitoring is not consistently implemented in these trials.
  • The findings suggest that the cardiovascular risks associated with cancer pharmacotherapy may be underestimated in clinical practice.